Lamivudina Aurobindo

Lamivudine, the active ingredient in Lamivudina Aurobindo, is a nucleoside reverse transcriptase inhibitor (NRTI) presented as an oral dosage form for oral use. It is employed in the treatment of HIV‑1 infection and chronic hepatitis B infection, helping to suppress viral replication and improve clinical outcomes.

GNH USA supplies Lamivudina Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support, and consistent quality for global health programs and ensuring compliance with local authorities.

Lamivudine is used in antiretroviral and antiviral therapy targeting viral replication pathways. - HIV-1 infection: reduces viral load and helps restore immune function. - Chronic hepatitis B infection: suppresses HBV replication and improves liver enzyme levels. - Prevention of mother‑to‑child transmission of HIV: lowers the risk of neonatal infection when included in combination regimens.

Lamivudine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Headache - Diarrhea

Serious or Rare Side Effects: - Lactic acidosis - Severe hepatotoxicity - Stevens‑Johnson syndrome

When prescribing lamivudine, several precautionary measures should be observed to ensure patient safety. - Renal impairment: assess kidney function and monitor for accumulation. - Hepatic impairment: use with caution and monitor liver enzymes. - Lactic acidosis risk: watch for unexplained fatigue, abdominal pain, or rapid breathing. - Pregnancy and breastfeeding: evaluate benefit‑risk ratio as safety data are limited. - Concomitant didanosine or stavudine: avoid combined use due to increased toxicity. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lamivudine interacts with several agents; awareness of these interactions helps avoid adverse outcomes.

Major Interactions (Avoid): - Didanosine: combined use increases risk of pancreatitis. - Stavudine: combined use heightens mitochondrial toxicity. - Rifampicin: may reduce lamivudine plasma concentrations.

Moderate Interactions (Monitor Closely): - Protease inhibitors boosted with ritonavir: may increase lamivudine levels. - Nephrotoxic drugs (e.g., tenofovir): monitor renal function. - Alcohol: may exacerbate liver toxicity.